Share
How immunotherapy works
Immunotherapy helps the immune system act against cancer. This is a group of treatments, not one single mechanism. Checkpoint inhibitors are a commonly used type. Other approaches include chimeric antigen receptor T-cell (CAR-T) therapy, which uses immune cells changed in a laboratory and follows a different treatment pathway.
Which immunotherapy does this page explain?
This guide mainly discusses immune checkpoint inhibitors. These medicines release particular brakes on immune activity so the immune system can recognise and attack cancer more effectively. They are different from supplements marketed as immune boosters. CAR-T cells, other cellular therapies and some antibody treatments use different mechanisms and have different precautions.
Immunotherapy can be used alone, with chemotherapy or targeted medicines, or as part of treatment around surgery in selected cancers. The combination is chosen for evidence in that disease setting. Receiving chemotherapy as well does not mean the immunotherapy is less advanced or that one treatment is being used merely as a backup.
Checkpoint inhibitors
Checkpoints help regulate immune activity. Some cancers use these signals to reduce an immune attack. Medicines acting on the checkpoint proteins programmed cell death 1 (PD-1), programmed death-ligand 1 (PD-L1), or other checkpoints can help restore anti-cancer immune activity. They do not work for everyone.
Who may benefit?
The cancer type, stage and treatment situation, previous treatment and biomarker findings influence selection. Biomarkers are measurable features, such as proteins or genetic changes. Testing for PD-L1, microsatellite instability (MSI), mismatch repair (MMR) and tumour mutational burden (TMB) is relevant in particular settings, but their meaning differs between cancers and treatments. A positive result does not guarantee benefit, and one biomarker cannot be interpreted in isolation.
Tests and health conditions that influence suitability
PD-L1, MMR, MSI and TMB may help select treatment in some cancers. TMB estimates the number of genetic mutations in the cancer; a high result may help identify an immunotherapy option in selected settings. The meaning of these tests depends on the tumour, test and proposed regimen. A positive result is not a guarantee of response; a negative result does not exclude every immunotherapy option. Some settings do not require these tests for the recommended treatment.
Tell your oncologist about autoimmune illness, an organ transplant, previous lung inflammation, infections and all medicines, especially steroids or immune-suppressing drugs. These factors may change the balance of benefits and risks. Do not stop a prescribed steroid yourself. Baseline blood tests and other assessments provide a comparison for later monitoring.
Planning your venous access
If your immunotherapy is given into a vein, discuss the options: a cannula (a small tube in a vein), a peripherally inserted central catheter (PICC, a longer line placed through an arm vein), or a port under the skin. The choice depends on the expected treatment duration and your veins. A central line is not automatically required; some treatments use other routes.
Ports, PICCs, and venous accessTreatment and monitoring
Checkpoint inhibitors are often given by infusion into a vein, alone or with other treatments. Some can also be given as an injection under the skin (subcutaneously), depending on the medicine and formulation available. Your schedule, planned duration and monitoring depend on your treatment plan (regimen) and treatment goal. Blood tests and symptom reviews help identify problems; imaging helps assess the cancer.
What to expect before and between appointments
Before treatment, agree how often you will attend, which tests are needed and when scans will assess benefit. At each visit, report changes from your usual health, including stool frequency, breathing, skin changes, appetite and energy. A symptom diary can help, particularly when several medicines are used together.
Keep a record of the immunotherapy name and the dates received. Show it to other clinicians, including in an emergency, and mention previous immunotherapy even after treatment has stopped. Some side effects appear late, so the end of treatment is not the end of symptom awareness.
Immune-related side effects
Immune activation can cause inflammation in healthy organs, including the bowel, lungs, liver, skin, hormone glands and, less commonly, the heart or nervous system. Problems can arise during treatment or after it has ended. Some need steroids, specialist care or long-term hormone replacement.
How immune-related symptoms are managed
Many symptoms can be managed more easily when reported early. The team first assesses possible causes, which can include infection, cancer or another medicine as well as immune inflammation. Blood tests, scans or specialist assessment may be needed. Do not assume that every new symptom is either harmless or definitely caused by immunotherapy.
Treatment may be temporarily withheld. Some immune side effects need corticosteroids or other medicines that reduce inflammation. Follow the prescribed course and taper rather than stopping suddenly. Some hormone-gland effects need hormone replacement for a long time. Whether immunotherapy can restart depends on the organ affected, severity and expected benefit.
Symptoms not to ignore
Report new diarrhoea, cough, breathlessness, marked weakness, severe headache, visual changes, unusual thirst or other new symptoms promptly. Severe symptoms need urgent assessment. Tell any treating clinician that you have received immunotherapy, even if treatment has finished.
Response and duration
Scans are interpreted alongside your symptoms and clinical condition. Occasionally response patterns differ from those seen with chemotherapy, but worsening symptoms must not be assumed to be a harmless treatment effect. The team decides whether to continue, investigate further or change treatment.
Daily life and planning ahead
Many patients continue ordinary activities, but fatigue or another symptom may require changes. There is no special diet or supplement proven to make checkpoint inhibitors work. Tell the team about supplements and discuss vaccinations, pregnancy prevention and travel before making plans.
Ask what support is available for work, emotional wellbeing and family responsibilities. A treatment that has fewer familiar chemotherapy effects can still need careful monitoring. Knowing when and how to get help is more useful than trying to predict every possible side effect.
Frequently asked questions
Is immunotherapy better than chemotherapy?
Neither is universally better. They work differently and are selected for a particular cancer and treatment goal. In some situations a combination has the strongest evidence; in others, one approach is preferred. Ask about the expected benefit of your actual regimen.
Does immunotherapy work for every cancer?
No. Its role depends on cancer type, stage, previous treatment and sometimes biomarkers. Even in an appropriate setting, not everyone responds. A clinician should explain both the reason for recommending it and the uncertainty.
Does a high PD-L1 result guarantee benefit?
No. PD-L1 can guide selection in certain settings, but it does not predict an individual outcome with certainty. The test method, score, tumour type and treatment combination all matter.
Can I benefit if PD-L1 is negative?
Sometimes. Certain recommended combinations or cancer settings do not require a positive PD-L1 result. Other biomarkers may be relevant. Your team should interpret the result in the context of the exact treatment being considered.
Is this the same as an immune-boosting supplement?
No. Checkpoint inhibitors act on specific immune-control pathways and have been studied in defined cancer settings. Supplements advertised as boosting immunity do not provide an equivalent treatment and may interact with prescribed care.
Will I lose my hair or feel sick?
These effects are less typical of checkpoint inhibitors alone than of some chemotherapy regimens, but they can occur. If chemotherapy is combined with immunotherapy, its side effects also apply. Ask for the expected pattern for all medicines in your regimen.
Can immunotherapy cause side effects after treatment ends?
Yes. Immune inflammation can appear during treatment or after it has stopped. Tell clinicians about previous immunotherapy when seeking help for new symptoms, and keep the treatment details with your medical records.
Which symptoms should I report straight away?
Contact the team promptly for new diarrhoea, cough, breathlessness, significant rash, marked weakness, severe headache, visual changes, unusual thirst or reduced urine. Severe breathing difficulty, chest pain, collapse or confusion needs emergency care. Do not wait for the next infusion.
Should I manage diarrhoea myself until the next visit?
Report new or worsening diarrhoea promptly. The team needs to assess possible infection or bowel inflammation and advise on treatment. Simply taking an antidiarrhoeal medicine may mask a problem that needs a different approach.
Will steroids cancel the benefit of immunotherapy?
Steroids are sometimes necessary to treat immune side effects safely. Their purpose, dose and timing matter. Do not avoid prescribed treatment because of this fear, or start or stop steroids yourself; discuss the plan with your oncologist.
Can I receive immunotherapy with an autoimmune condition?
Sometimes, but it needs an individual discussion of the risk of a flare or new immune effects. The team may involve the specialist managing the autoimmune disease. The diagnosis and medicines you already take are important.
What if I have had an organ transplant?
Checkpoint inhibitors can trigger rejection of a transplanted organ. This requires a careful specialist discussion before treatment. Make sure your cancer team knows the transplant history and current anti-rejection medicines.
How long will treatment continue?
Some plans have a defined course; others continue while there is benefit and acceptable side effects, subject to the regimen. There is no universal duration. Ask what would lead to stopping, pausing or changing your treatment.
Does a larger tumour on the first scan mean treatment has failed?
Not always, but true progression is an important possibility. An uncommon immune-related response pattern can cause apparent early enlargement. Your team considers symptoms, timing and sometimes repeat assessment. Worsening health must not be dismissed as this phenomenon.
Can treatment work without major side effects?
Yes. Having no obvious immune side effects does not mean treatment is ineffective. Similarly, a side effect is not proof of benefit. Response is assessed separately using the appropriate clinical checks and scans.
Can I restart after a side effect?
Sometimes, after recovery and specialist review. Serious inflammation in certain organs may make restarting unsafe. The decision considers what happened, whether ongoing treatment is needed and the available alternatives.
Do I need a port for the infusions?
Not always. A cannula may be suitable; a PICC or port may help with repeated treatment or difficult veins. The full regimen, infusion schedule and your preferences guide the choice.
Can I have vaccines or plan a pregnancy?
Discuss both before treatment. Vaccine choice and timing depend on your medicines and immune status. Pregnancy and breastfeeding precautions are drug-specific and continue for a defined period after some treatments; ask for written advice.
